NASDAQ: BNTX - Invest Million

Pfizer-BioNTech Decides to Develop Booster Vaccine for Delta Variant

Pfizer, Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) disclosed that they have decided to develop a new shot that targets the new variant which is called Delta Variant.

Pfizer Inc. (PFE)

Pfizer-BioNTech to Deliver 1.8 Billion Additional Doses of COMIRNATY to EU

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) disclosed that the firms are preparing to deliver 1.8 billion additional doses of COMIRNATY to European Unions.

BioNTech SE (BNTX)

BioNTech (NASDAQ: BNTX) to Start mRNA Manufacturing Facility in Singapore

BioNTech SE (NASDAQ: BNTX) disclosed Monday that it has decided to start a new mRNA manufacturing facility in Singapore.

Pfizer Inc. (PFE)

Pfizer-BioNTech To Deliver Additional 200M Doses Of COMIRNATY

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) revealed that the firms have signed an agreement with the European Commission (EC). As per the deal, the firms will deliver additional 200 million doses of COMIRNATY

$BNTX

BioNTech (NASDAQ: BNTX) Inks Deal With InstaDeep To Develop Novel Immunotherapies

BioNTech SE (NASDAQ: BNTX) has signed a strategic partnership contract with InstaDeep Ltd. Both the companies are planning to use the latest technologies such as machine learning and artificial intelligence to develop a cure for cancers and other infectious diseases. As per the deal,

BioNTech SE (BNTX)

Pfizer-BioNTech Secures 300M COVID19 Vaccine Doses Deal With EU

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) revealed today that it has entered into an agreement with the European Commission for the supply of COVID-19 vaccine. As per the agreement, Pfizer-BioNTech will provide 200 million doses of their ‘90% effective’

BioNTech SE (BNTX)

Pfizer And BioNTech COVID19 Vaccine Candidate Achieve 90% Success In Phase III Study

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have revealed today that the COVID-19 vaccine candidate, BNT162b2, has shown encouraging results in the first interim analysis from the Phase III study. The independent Data Monitoring Committee (DMC) has reviewed the mRNA-based vaccine candidate